Company Profile
Suzhou Zelgen Biopharmaceuticals provides the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer recombinant human thrombin for hemostasis.
It also develops gecacitinib hydrochloride tablets for severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, moderate to severe plaque psoriasiste, idiopathic pulmonary fibrosis, and myelofibrosis.
Its portfolio also includes recombinant human thyroid-stimulating hormone for injection, and ZG006 for injection, indications for small cell lung cancer, neuroendocrine carcinoma, and advanced tumors. Additionally, it develops ZG005 for injection, which is in phase I/II clinical trial for cervical cancer, liver cancer, neuroendocrine carcinoma and advanced tumors
ZGGS18, ZGGS15, ZGGS34, ZG016, ZG2273, ZG2001film, and ZG0895 hydrochloric acid for injection indications for advance tumors. Its products serve multiple therapeutic areas, such as tumors and hematological diseases, bleeding and trauma, and immune inflammatory diseases. Founded in 2009, Suzhou Zelgen Biopharmaceuticals is based in Kunshan, the People's Republic of China.